Market capitalization | $151.91m |
Enterprise Value | $575.60m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 1.17 |
P/S ratio (TTM) P/S ratio | 0.31 |
P/B ratio (TTM) P/B ratio | 0.72 |
Revenue growth (TTM) Revenue growth | -14.27% |
Revenue (TTM) Revenue | $490.74m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
3 Analysts have issued a Inotiv Inc forecast:
3 Analysts have issued a Inotiv Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 491 491 |
14%
14%
|
|
Gross Profit | 54 54 |
59%
59%
|
|
EBITDA | -13 -13 |
121%
121%
|
EBIT (Operating Income) EBIT | -76 -76 |
3,102%
3,102%
|
Net Profit | -108 -108 |
3%
3%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Inotiv, Inc. operates as a pharmaceutical development company, which engages in the provision of drug discovery, development services, and analytical instruments. The firm operates through the following business segments: Contract Research Services and Research Products. The Contract Research Services segment provides screening and pharmacological testing, preclinical safety testing, formulation development, regulatory compliance, and quality control testing. The Research Products segment designs, develops, manufactures, and markets vivo sampling systems and accessories, physiology monitoring tools, liquid chromatography, and electrochemistry instruments platforms. The company was founded by Peter T. Kissinger in 1974 and is headquartered in West Lafayette, IN.
Head office | United States |
CEO | Robert Leasure |
Employees | 2,075 |
Founded | 1974 |
Website | www.inotivco.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.